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ORIGINAL ARTICLE
Polygenic inheritance of paclitaxel-induced sensory peripheral
neuropathy driven by axon outgrowth gene sets in CALGB 40101
(Alliance)
A Chhibber1,2, J Mefford2,3, EA Stahl4,5,14, SA Pendergrass6, RM Baldwin1,2, K Owzar7, M Li1,2, EP Winer8, CA Hudis9, H Zembutsu10,
M Kubo11, Y Nakamura10,11,12, HL McLeod13, MJ Ratain12, LN Shulman8, MD Ritchie6, RM Plenge4,5, JS Witte2,3 and DL Kroetz1,2
Peripheral neuropathy is a common dose-limiting toxicity for patients treated with paclitaxel. For most individuals, there are no
known risk factors that predispose patients to the adverse event, and pathogenesis for paclitaxel-induced peripheral neuropathy is
unknown. Determining whether there is a heritable component to paclitaxel-induced peripheral neuropathy would be valuable in
guiding clinical decisions and may provide insight into treatment of and mechanisms for the toxicity. Using genotype and patient
information from the paclitaxel arm of CALGB 40101 (Alliance), a phase III clinical trial evaluating adjuvant therapies for breast
cancer in women, we estimated the variance in maximum grade and dose at ﬁrst instance of sensory peripheral neuropathy. Our
results suggest that paclitaxel-induced neuropathy has a heritable component, driven in part by genes involved in axon outgrowth.
Disruption of axon outgrowth may be one of the mechanisms by which paclitaxel treatment results in sensory peripheral
neuropathy in susceptible patients.
The Pharmacogenomics Journal (2014) 14, 336–342; doi:10.1038/tpj.2014.2; published online 11 February 2014
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INTRODUCTION
Peripheral neuropathy is a common and often dose-limiting
toxicity associated with cancer chemotherapy treatment. Pacli-
taxel is a chemotherapeutic agent in the taxane family and func-
tions by inhibiting microtubule assembly and inducing apoptosis.
It is commonly prescribed in the treatment of carcinomas of the
breast, ovary, lung and head and neck.1 Sensory peripheral
neuropathy induced by paclitaxel is dose-dependent and is the
most common toxicity associated with this microtubule inhibitor.
Severe toxicity (Grade 3 or higher) generally occurs in 5–10% of
patients although rates as high as 30% have been reported for
certain dosage regimens.2 Known risk factors for paclitaxel-
induced neuropathy include previous exposure to a neurotoxic
agent or medical conditions associated with peripheral neuro-
pathy, such as diabetes,2–6 though most patients who suffer from
paclitaxel-induced neuropathy do not have an identiﬁable
predisposition. The pathogenesis of paclitaxel-induced peripheral
neuropathy is unclear. Paclitaxel treatment may target axons,
myelinating Schwann cells, or the dorsal root ganglion and neuron
cell bodies of peripheral nerves.7 At any of these sites, damage
may be mediated by microtubule stabilization or mitochondrial
disruption.8 At very high single or cumulative doses almost all
patients will experience some degree of peripheral neuropathy,
but in certain susceptible patients neuropathy will occur at lower
cumulative doses or with greater severity. Interindividual suscep-
tibility to paclitaxel-induced peripheral neuropathy may be driven
by an overall increase in exposure to paclitaxel or an increased
sensitivity to damage or decreased capacity for repair at any of the
putative targets of paclitaxel in the peripheral neuron.
Given the wide interindividual variability in incidence and
severity of the toxicity independent of any known risk factors, it is
likely that there is an underlying genetic basis for susceptibility
to paclitaxel-induced neuropathy. Small candidate gene studies
focusing on genes involved in paclitaxel pharmacokinetics and
pharmacodynamics (for example, ABCB1, CYP2C8) or paclitaxel
targets (for example, b-tubulin) have had mixed results, with some
identifying variants associated with neuropathy9–11 and others
failing to replicate previous results.12,13 Recently, a genome-wide
association study from this group14 identiﬁed several single-
nucleotide polymorphisms (SNPs) with moderate effect size in
FZD3, FGD4 and EPHA5 associated with severity or dose at onset of
paclitaxel-induced sensory peripheral neuropathy. An indepen-
dent genome-wide study identiﬁed SNPs in RWDD3 and TECTA
associated with onset of paclitaxel-induced neuropathy,15 but
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these ﬁndings were not replicated by others.16 The large number
of putative causative variants identiﬁed, many with small
effect size, and the discrepancies from study to study suggest a
complex polygenic etiology for susceptibility to paclitaxel-induced
neuropathy.
Pharmacogenomic studies, especially those involved in the study
of drug toxicities, come with their own particular set of challenges.
Sample sizes are often limited, and phenotype deﬁnitions can be
imprecise.17 This is compounded in cases where the toxicity does
not appear to be driven by one or a few polymorphisms with
large effect size, such as CYP2D6 polymorphisms and morphine
toxicity,18 but rather by a number of variants each with small
potential contribution to disease, as we propose is the case for
paclitaxel-induced peripheral neuropathy. For these phenotypes,
determining the extent to which genetic variability contributes to
a particular toxicity can be challenging. Traditional heritability
studies require large numbers of siblings or family structures that
are not practicable, especially when studying potentially toxic
drugs. Even when evidence for a heritable component to toxicity
is available, candidate gene/candidate variant studies or tradi-
tional genome-wide association studies will likely be unable to
identify variants with small effects that together explain a large
portion of the expected heritability.
Recently, a method has been developed to estimate additive
genetic variation or narrow-sense heritability driven by common
SNPs (that is, those typically captured on genotyping platforms) in
unrelated individuals using linear mixed models.19,20 This approach
was applied to genome-wide SNP data in breast cancer patients
treated with paclitaxel to determine the extent to which pacli-
taxel-induced sensory peripheral neuropathy is heritable and to
identify causal SNPs driving this heritability.
MATERIALS AND METHODS
Patient data and study design
The patient cohort for this study was taken from the paclitaxel arm of
CALGB 40101 (Alliance), a Phase III trial studying adjuvant therapy for
patients with breast cancer; all patients in the current study were also
enrolled in CALGB 60202 (Alliance), the pharmacogenomic companion
study, and signed an IRB (Institutional Review Board)-approved, protocol-
speciﬁc informed consent for use of their specimens. Paclitaxel was
administered every 2 weeks over 3 h at 175mgm 2 for four or six cycles. A
total of 1040 paclitaxel-treated individuals were included in the cohort;
after quality control, including principal component analysis, call rate
(498%) and clustering performance, 859 Caucasian patients were retained
for further analysis. Germline DNA was genotyped on the HumanHap610-
Quad Genotyping BeadChip (Illumina) platform. SNP quality control mea-
sures for minor allele frequency (X0.01), genotyping call rate (X99%) and
Hardy–Weinberg equilibrium in controls (exact test PX0.001) were applied
using PLINK (v1.07). Genotyped data was imputed to call genotypes of un-
typed SNPs using MACH21,22 (1.0) and the 1000 Genomes23 Pilot I (June
2010) data from unrelated Caucasian (CEU) individuals as a reference;
imputed data were ﬁltered for r240.9. Recent publications describe further
details regarding the pharmacogenomic14 and clinical24 studies. Details
regarding patient selection, SNP quality control and imputation are
outlined in Supplementary Figure S1.
Phenotype
Two phenotypes are of interest in studying paclitaxel-induced
neuropathy—severity of the neuropathy and cumulative dose at onset
of neuropathy. These outcomes may be driven by distinct or overlapping
sets of genes. Peripheral neuropathy was graded on a scale of 0–5
according to the National Cancer Institute Common Toxicity Criteria for
Adverse Events (NCI-CTCAE) version 2.0. The distribution of neuropathy
grades in our cohort (Figure 1) matches expected numbers from previous
clinical trials.25,26 Because the linear mixed modeling approach requires a
continuous quantitative or binary phenotype, both severity of neuropathy
and dose at onset of neuropathy were treated as continuous variables.
Severity of neuropathy was modeled using the highest grade of neuro-
pathy over the course of treatment with log-transformed cumulative dose
administered at highest grade of neuropathy (mgm 2) as a covariate. For
patients who did not experience the toxicity, cumulative dose admini-
stered over the course of the study was used as the covariate. Onset of
neuropathy was modeled using deviance residuals from a time-to-event
analysis as a continuous phenotype. The deviance residuals are a
normalized transform of the martingale residuals, which estimate the
difference at a particular cumulative dose t between observed (incidence
of grade 2 or higher peripheral neuropathy, 0 or 1) and expected events
(predicted hazard for neuropathy at dose t) for a given patient. Residuals
from survival models have been previously used to model time to onset of
various phenotypes as a quantitative trait when it is not possible to apply a
survival model directly.27–29 The time-to-event analysis was conducted
using a null Cox proportional hazards model without predictors, with time
deﬁned as cumulative paclitaxel dose and event deﬁned as ﬁrst instance of
grade 2 or higher peripheral neuropathy.14 For patients who did not
experience grade 2 or higher neuropathy, cumulative dose administered
over the course of the study was used, producing right-censored dosage
date. Deviance residuals from the Cox score test were calculated using the
survival package in R.30,31
Pathway deﬁnitions
Pathways evaluated were selected based on putative pathology for pacli-
taxel-induced neuropathy. Five Gene Ontology32 (GO Release 2012-09-15)
Biological Process terms were included: Axonogenesis (GO: 0007409),
Myelination (GO: 0042552), Transmission of Nerve Impulse (GO: 0019226),
Microtubule-Related Processes (GO: 0007017), and Mitochondrial Organiza-
tion and Transport (GO: 0006839 and 0007005), along with a manually
curated set of genes associated with congenital peripheral neuropathy33
and a set of genes in the paclitaxel pharmacokinetic/pharmacodynamic
pathway.34 For GO terms, all possible genes (regardless of evidence code)
were included. For each pathway, gene boundaries for the largest isoform
of each gene were extracted from the UCSC Table Browser using UCSC gene
annotations from human genome build 37 (hg19). These gene boundaries
(plus an additional 10kb upstream and downstream) were used to extract all
dbSNP13535 SNPs in the gene regions. Pathway SNP lists were used to
extract the pathway-speciﬁc portion of the genome in PLINK (v1.07).36
For SNP sets grouped by position in the genome (genic vs intergenic),
gene and SNP annotations were extracted from the UCSC Table Browser
using CCDS37 gene annotations from human genome build 37 (hg19) and
SNP annotations from dbSNP135. Genic regions were deﬁned as 10 kb
upstream and downstream of transcription start and stop sites. For genes
with multiple CCDS isoforms, the longest isoform was used. The Bioﬁlter38
software (v2.0.0) was used to extract SNPs by genomic position.
Linear mixed modeling heritability analysis
Heritability estimates for the whole genome and for the pathways were
generated using the Genome-Wide Complex Trait Analysis (GCTA) (v1.01)
Figure 1. Distribution of sensory peripheral neuropathy in the study
population. The distribution of the highest reported grade of
sensory peripheral neuropathy is shown for 849 unrelated genetic
Europeans from the paclitaxel arm of CALGB 40101. Toxicity is
measured using the NCI-CTCAE Scale v2.
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software tool.39 We estimated the genetic-relatedness matrix (GRM) for 859
Caucasians using all post-quality control genotyped SNPs. Principal com-
ponents analysis was conducted using GCTA, and the ﬁrst 20 eigenvectors
for each individual were used as covariates in all subsequent analyses to
control for any remaining population stratiﬁcation. To ensure that all
subjects in the study were unrelated, we excluded one of each of a pair of
individuals with genetic relationship 40.03, roughly corresponding to
second cousins or closer familial relationships; 10 individuals were excluded
in this step. An additional four individuals were excluded due to incomp-
lete phenotype information for a ﬁnal population of 845 unrelated
Caucasians (Supplementary Figure S1). All analyses were restricted to
autosomes and were conducted with the assumption that causal SNPs will
have the same allele frequency distribution as genotyped SNPs.
For pathway speciﬁc heritability analyses, a separate GRM was
constructed for each pathway and for its complement (whole-genome
GRM excluding SNPs in the pathway) using the set of 845 unrelated
Caucasians. Total genetic variance for severity and onset of neuropathy
was partitioned simultaneously onto pathway and ‘non-pathway’ SNPs.
Likewise, for genomic position-based heritability analyses, total genetic
variance for both phenotypes was partitioned onto genic and intergenic
regions. To correct for the simultaneous evaluation of multiple pathways,
GCTA P-values were Bonferroni-corrected by multiplying each P-value by
the number of pathways tested together (7 in the ﬁrst round and 10 in the
second round). Empirical distributions representing the null hypothesis
that the trait is not heritable were generated as follows for each pathway-
speciﬁc heritability estimate: for severity of neuropathy, residuals and
expected values were extracted from linear regression of grade of
neuropathy with log cumulative dose of paclitaxel and the ﬁrst 20
principal components. For each of 1000 permutations, residuals were
permuted, summed with expected values for each individual and used to
estimate pathway-speciﬁc heritability in GCTA. For onset of neuropathy,
deviance residuals were calculated as described, and then input as an
independent variable in a linear regression including 20 principal
components from which residuals and expected values were extracted.
As with severity of neuropathy, for each of 1000 permutations, residuals
were permuted, summed with expected values for each individual and
used to estimate pathway-speciﬁc heritability in GCTA. Empirical P-values
were generated by calculating the probability of obtaining a heritability
estimate greater than that estimated from observed data.
PLINK set test
Brieﬂy, the PLINK set test as implemented in this study calculates the mean
of all signiﬁcant (Po0.05) per-SNP P-values after ﬁltering for SNPs in
linkage disequilibrium (r2X0.5). An empirical P-value is applied to each set
test by permuting phenotype labels across individuals. SNP P-values for
severity and onset of neuropathy were calculated in PLINK by linear
regression of residuals from regression of grade of neuropathy on number
of minor alleles, with log cumulative dose of paclitaxel and principal
components as covariates in both initial regression and PLINK set test.
RESULTS
The variance explained by common (minor allele frequency41%)
SNPs for paclitaxel-induced neuropathy was estimated in a cohort
of 845 unrelated Caucasian breast cancer patients treated with
single agent paclitaxel. Two outcomes were of interest—severity
of neuropathy (measured on a grade of 0–5) and cumulative dose
administered at onset of neuropathy (Xgrade 2), both treated as
continuous quantitative variables. The variance explained by all
genotyped SNPs across the genome was estimated as 41% for
severity of neuropathy and 55% for onset of neuropathy but with
high standard errors (44% and 47%, respectively) due to the small
sample size. To narrow in on the causative SNPs driving heritability
and reduce noise from non-causative SNPs, two methods were
applied: (1) a genomic position based SNP selection, extracting
SNPs in genic regions, and (2) a biological pathway-based
selection that extracted SNPs that fall in biological pathways that
are associated with putative mechanisms for susceptibility to
paclitaxel-induced neuropathy.
When partitioning the genome in SNP sets by genomic location
(Figure 2), a trend toward higher heritability was found in genic
regions for severity (h2¼ 49±37%, P¼ 0.07) and onset of
peripheral neuropathy (h2¼ 48±35%, P¼ 0.08). For severity of
peripheral neuropathy, pathway-speciﬁc results show highest
heritability estimates for the Axonogenesis gene set (h2¼ 21±
12%, P¼ 0.040; Table 1). A complementary pathway analysis
approach, the PLINK set test, was used to further extend our
pathway-based heritability results. Consistent with the GCTA
analysis, only the Axonogenesis set is signiﬁcant (P¼ 0.012) for
severity of neuropathy using the set test (Supplementary Table
S1). For onset of peripheral neuropathy, no signiﬁcant signal of
heritability was detected in any of the pathways tested
(Supplementary Table S2).
‘Children’ of the GO Axonogenesis term, deﬁned as terms with a
‘is_a’ or ‘part_of’ relationship with the Axonogenesis term, were
subsequently tested for the severity of neuropathy phenotype
(Table 2). Of the 10 terms tested, GO Regulation of Axonogenesis
(GO: 0050770), GO Axon Extension (GO: 0048675) and GO CNS
Neuron Axonogenesis (GO: 0021955) showed strong heritability
signals (h2¼ 13±6% (P¼ 0.009), 10±5% (P¼ 0.020) and 5±3%
(P¼ 0.020), respectively). To determine whether the signal from
these three terms comes from independent genes in each set or
overlapping genes in the three sets, heritability estimates were
calculated using the pair-wise and three-way union or intersection
of the GO Regulation of Axonogenesis, GO Axon Extension and GO
CNS Neuron Axonogenesis sets. The union or intersection of the
GO CNS Neuron Axonogenesis set with GO Axon Extension or GO
Regulation of Axonogenesis sets resulted in lower heritability
estimates than either independent set with high s.e. (data not
shown). For the GO Axon Extension and GO Regulation of
Axonogenesis sets, the heritability signal from each independent
set and the union and intersection sets are very similar (Figure 3),
suggesting that a large portion of the SNPs driving the heritability
in the Regulation and Extension sets come from the 44 genes
found in both gene sets.
Heritability estimates were also calculated using imputed data;
as with the genotyped SNPs, whole-genome estimates of
heritability with imputed SNPs had very high standard errors.
For genomic position and pathway analyses, results from imputed
data were similar to those described above for genotyped data,
with a trend to higher heritability estimates in genic vs intergenic
regions for the severity of peripheral neuropathy (Supplementary
Table S3) and in the GO Axonogenesis set for severity of
peripheral neuropathy (Supplementary Tables S4–S6).
Figure 2. Heritability estimates for severity and onset of paclitaxel-
induced sensory peripheral neuropathy for single-nucleotide poly-
morphisms in genic and intergenic regions. Total genomic variance
for both severity and onset of neuropathy was partitioned onto
genic and intergenic regions. The error bars denote the s.e. for the
heritability estimates.
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DISCUSSION
These results suggest that a portion of variation in severity and
onset of paclitaxel-induced sensory peripheral neuropathy is
captured by additive effects of common SNPs in this clinical trial
population. Previous studies have indicated that heritability is
driven primarily by SNPs in genic regions,40 and a similar trend is
found in our study. Within genic regions, we also noted a higher
proportion of variance in severity and onset of peripheral
neuropathy captured by SNPs in intronic regions (data not
shown), but it is unclear whether this is due to a bias in the
design of the genotyping chip or true bias in the genomic location
of SNPs associated with paclitaxel-induced neuropathy. If real, the
enrichment of heritability signal in introns suggests that the
majority of causal SNPs have subtle biological effects—for
example, small changes in expression or stability that may be
regulated by intronic SNPs, rather than overt changes in protein
structure or function caused by variation in exons. This is
consistent with a polygenic model in which many small, additive
effects together contribute to the phenotype.
Further, a set of genes was identiﬁed that drive a substantial
portion of the heritability of severity of paclitaxel-induced
peripheral neuropathy, implicating axonogenesis and, more
speciﬁcally, the regulation of axon outgrowth, in the pathophy-
siology of this adverse event. These results are supported by
evidence from human biopsies, electrophysiological studies and
Table 1. Heritability estimates for severity of paclitaxel-induced sensory neuropathy using SNPs in biological pathways implicated in the toxicity
Pathway Heritability estimates Pathway characteristics
V(G)/V(p)a s.e. Pb Padjc Empirical Pd No. of genes Size (Mb) No. of SNPs
GO Axonogenesis 0.213 0.120 0.040 0.28 0.011 502 78.0 17 581
GO Impulse Transmission 0.000 0.122 0.500 1 0.999 746 106 22 886
GO Myelination 0.029 0.035 0.200 1 0.255 75 6.86 1336
Congenital Peripheral Neuropathy 0.000 0.030 0.500 1 0.999 40 4.03 947
Paclitaxel Pharmacokinetics/Pharmacodynamics 0.011 0.017 0.300 1 0.221 10 1.20 402
GO Mitochondrial Transport and Organization 0.012 0.055 0.400 1 0.545 274 19.7 3668
GO Microtubule-Related Processes 0.000 0.072 0.500 1 0.999 34 3.55 5775
Abbreviations: GO, Gene Ontology; SNP, single-nucleotide polymorphism. aHeritability was estimated for sets of SNPs within±10 kb of genes in biological
pathways implicated in the pathophysiology of paclitaxel-induced sensory peripheral neuropathy. The congenital neuropathy and paclitaxel
pharmacokinetics/pharmacodynamics pathways were manually constructed from the literature. bP-value from GCTA (genome-wide complex trait analysis).
Software upper limit for P-value is 0.5; maximal values are noted as 1. cP-value corrected for seven observations. dP-value from permutation analysis.
Table 2. Heritability estimates for severity of neuropathy captured by SNPs in subsets of the GO Axonogenesis set
GO Axonogenesis children Heritability estimates Pathway characteristics
V(G)/V(p)a s.e. Pb Padjc Empirical Pd No. of genes Size (Mb) No. of SNPs
Axonal Fasciculation 0.000 0.025 0.5 1 0.999 15 2.89 922
Peripheral Neuron Axonogenesis 0.005 0.010 0.3 1 0.203 2 0.13 15
Axon Guidance 0.000 0.019 0.5 1 0.999 362 57.51 699
Axonogenesis in Innervation 0.011 0.015 0.2 1 0.146 3 0.15 19
Axon Regeneration 0.000 0.013 0.5 1 0.999 29 3.31 314
CNS Neuron Axonogenesis 0.051 0.031 0.020 0.2 0.028 26 6.32 935
Axon Extension 0.097 0.050 0.020 0.2 0.003 70 8.88 1862
Regulation of Axonogenesis 0.130 0.059 0.009 0.09 0.001 104 20.85 3239
Collateral Sprouting 0.012 0.019 0.3 1 0.26 13 3.10 396
Axon Target Recognition 0.000 0.010 0.5 1 0.999 4 0.27 34
Abbreviations: CNS, central nervous system; GO, Gene Ontology; SNP, single-nucleotide polymorphism. aHeritability was estimated for sets of SNPs
within±10 kb of genes in children (subsets) of the GO Axonogenesis set. bP-value from GCTA (genome-wide complex trait analysis). Software upper limit for
P-value is 0.5; maximal values are noted as 1. cP-value corrected for 10 observations. dP-value from permutation analysis.
Figure 3. Heritability estimates for severity of paclitaxel-induced
sensory peripheral neuropathy for single-nucleotide polymorphisms
(SNPs) in selected Gene Ontology (GO) biological pathways.
Heritability was estimated for sets of SNPs within all pathways
contained within the GO Axonogenesis pathway. Results are shown
(heritability±s.e.) for those pathways with significant (Po0.05)
heritability signals. The heritability estimates for the intersection
between and union of the Axon Extension and Regulation of
Axonogenesis are also shown.
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animal- and cell-based models that paclitaxel causes a distal
axonopathy, in which the degeneration of axons occurs ﬁrst at
axon ends. This pattern of neuronal damage is consistent with a
length-dependent neuropathy, targeting the long axons that
extend into the hands and feet ﬁrst, as typically occurs with
paclitaxel-induced neuropathy.41–44 Further, there is evidence that
demyelination and ganglionopathy, if they do occur, are
secondary to axon damage.41,44,45 The current results suggest
that susceptibility to paclitaxel-induced neuropathy is caused in
part by heightened sensitivity to or reduced capacity to repair this
distal axon damage.
Of the 44 genes in the GO Axon Extension and GO Regulation of
Axonogenesis overlap set (Supplementary Table S7), a number of
genes have been implicated in neuropathy, including hereditary
neuropathy genes (MAP1B,46 NGF,47FXN48), genes with variants or
expression signatures associated with diabetic or HIV-induced
peripheral neuropathy (APOE,49,50 MAPT,51 CDH451), genes involved in
neurological pain pathways (MT3,52 TRPV2,53 CCR5,54 CXCL1255)
and genes involved in response to or repair/prevention of
peripheral nerve damage (RYK,56 SLIT1,57 NTRK3,58 NGF,59,60
TRPV2,53 NTN1,61 NDEL162). The majority (38) of these 44 genes
fall in the GO term Regulation of Axon Extension (GO 0030516),
which is a subset of both GO Regulation of Axonogenesis and GO
Axon Extension.
The pathway results are also consistent with gene expression
analyses in mouse and human studies of diabetic neuropathy. In a
study examining the pathophysiology of diabetes-induced neuro-
pathy, the GO Axonogenesis term was identiﬁed as an over-
represented pathway in a differential expression analysis in the
db/db vs db/þ mouse sciatic nerve.51 Similarly, the GO Regulation
of Axonogenesis term was identiﬁed as an over-represented
set in genes upregulated in sural nerve biopsies from patients
with advanced progression of diabetic neuropathy.63 Although
neuron damage is caused by different mechanisms in diabetes
and following paclitaxel treatment, these results suggest that
susceptibility to sensory peripheral neuropathy is driven by the
same sets of genes.
Despite success in estimating heritability for paclitaxel-induced
neuropathy and identifying a subset of the genome driving this
heritability, some limitations in available methods and data are
noted. One of the primary limitations of any pathway or gene set-
based analysis is the gene set deﬁnitions available. All available set
deﬁnitions are limited by current knowledge about the pathway in
question, and well-curated sets are restricted to those pathways of
interest to researchers. Further, the number of SNPs captured per
gene varies, either because of true differences between number of
variants or haplotype structure between genes or because of
differences in coverage between genes on the genotyping
platform that was used. Such variability in local coverage is
known to be a limitation in all commercial genotyping plat-
forms.64 Although imputation of missing SNPs did increase SNP
density in each set, heritability estimates with imputed data were
close to those with just genotyped data; because of the high
imputation quality threshold used (r240.9), it is likely that
additional SNPs are in high linkage disequilibrium with geno-
typed SNPs, adding little additional information. For onset of
peripheral neuropathy, no signiﬁcant signal of heritability was
detected in any of the pathways tested, either because genes
driving heritability of onset of neuropathy are in a pathway we did
not select or because the use of deviance residuals from the Cox
proportional hazards regression rather than a direct proportional
hazards regression did not adequately model the data. It is also
possible that one or more of the selected pathways is incom-
pletely annotated. GO terms are annotated using a combination of
experimental evidence and computational analyses and can be
both manually and electronically annotated.32,65 The extensive set
of sources for term annotation not only makes GO the most
comprehensive source of annotated terms available but also
contributes to signiﬁcant noise (incorrectly assigned genes) being
built into the terms. Unfortunately, highly accurate manually
annotated gene sets are currently limited, and those that exist
reﬂect the current body of knowledge regarding a given pathway.
The GO was the only database that included gene sets for each of
the peripheral neuropathy mechanisms of interest. For the GO set
Axonogenesis, more restrictive set deﬁnitions were investigated,
including limiting pathway genes to those annotated to
Axonogenesis by experimental evidence and those that were
direct associations. The GO Axonogenesis experimental set gave
an estimate of heritability signiﬁcantly lower than that derived
from the complete gene set (8% vs 22% for the complete set),
suggesting that using a more conservative gene annotation would
result in loss of power (Supplementary Table S8).
The standard errors for the whole-genome heritability analyses
are high owing to the limited sample size. Large sample sizes are
difﬁcult to obtain in genomic studies of drug toxicities, as
recruitment into these studies is often limited to existing clinical
trials. However, by narrowing in on the ‘causative’ SNPs, signals of
heritability were obtained even with relatively small sample sizes.
In this study, constraints were also imposed by the linear mixed
modeling method applied, which requires a continuous or
dichotomous phenotype. Although severity of neuropathy is best
modeled as an ordinal variable, it is treated as a continuous
quantitative variable for the purpose of this study. Likewise, onset
of neuropathy is best ﬁt in a survival model, but deviance residuals
from a survival model were used as a continuous trait in the
current analysis. Despite these limitations, the results from the
modiﬁed phenotype deﬁnitions are likely close to those that
would be estimated from the application of non-linear phenotype
deﬁnitions. For example, effect estimates for SNPs in biological
pathways from severity of neuropathy modeled as a linear or
ordinal variable (Supplementary Figure S2) or onset of neuropathy
modeled as a linear phenotype or time-to-event analysis
(Supplementary Figure S3) are highly correlated (r2¼ 0.91 and
0.97, respectively). However, it is important to note that, because
of the constraints on the phenotype deﬁnition, we treat heritability
estimates obtained from our analyses simply as an indication of
association between a certain sets of SNPs and our phenotypes of
interest, rather than absolute measures of percentage of variance
explained by a particular SNP set. Finally, a gene boundary cutoff of
10 kb was selected to ensure that the SNPs are associated with the
genes in our pathway (as opposed to a neighboring gene), though
at the cost of losing potential causative SNPs in upstream and
downstream regulatory regions of a gene. Because most genetic
variability appears to be explained by SNPs in or near genes,40 our
approach likely captures a signiﬁcant fraction of the variability
explained by the genes in a given set.
In summary, these results suggest that there is a heritable
component to the severity and dose to onset of paclitaxel-induced
sensory peripheral neuropathy. Further, genes involved in axon
outgrowth may modulate the severity of paclitaxel-induced
neuropathy. Understanding the mechanisms and pathways
involved in susceptibility to paclitaxel-induced sensory peripheral
neuropathy will help identify therapies that can mitigate the
toxicity and guide future drug development.
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